Atypical chronic myeloid leukemia in patients after breast cancer treatment
02/2019
MUDr. Jana Zuchnická1, MUDr. Petra Richterová1, MUDr. Zuzana Rusiňáková2, prof. MUDr. Edgar Faber, CSc.2, MUDr. Roman Hájek, CSc.1
1 Klinika hematoonkologie FN a LF OU, Ostrava
2 Hemato-onkologická klinika FN Olomouc a LF UP, Olomouc
SUMMARY
Atypical chronic myeloid leukemia BCR/ABL1 negative is a rare disease. The prognosis is unfavorable; patients have a high risk of transformation in acute myeloid leukemia. Transplantation of allogeneic haematopoietic stem cells should therefore be considered in younger patients without significant associated illnesses for which a suitable donor has been found early in the course of disease. We use paliative treatment procedures for patients who are unsuitable for transplantation.
Key words
atypical chronic myeloid leukemia, myelodysplastic-myeloproliferative disease, granulopoiesis dysplasia, allogeneic haematopoietic stem cell transplantation
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...